The present application describes novel barbituric acid derivatives of formula I: ##STR1##

or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R¹, W, Z, U^a, X^a, Y^a, and Z^a are defined in the present specification, which are useful as TNF- converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.